Published in Clin Cancer Res on March 01, 2000
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A (2004) 2.00
Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol (2009) 1.64
Activation of latent HIV using drug-loaded nanoparticles. PLoS One (2011) 1.10
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol (2009) 1.09
Bryostatin 1 inhibits phorbol ester-induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) delta translocation and preventing PKCdelta-mediated release of tumor necrosis factor-alpha. Mol Pharmacol (2010) 0.96
Marine-derived angiogenesis inhibitors for cancer therapy. Mar Drugs (2013) 0.89
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer (2001) 0.86
Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanism. Sci Rep (2015) 0.85
Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest New Drugs (2001) 0.82
The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion. Haematologica (2011) 0.79
The Novel PKCθ from Benchtop to Clinic. J Immunol Res (2015) 0.78
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer. Br J Cancer (2003) 0.76
A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs (2002) 0.75
Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs (2002) 0.75
Protein kinase C in cellular transformation: a valid target for therapy? Biochem Soc Trans (2014) 0.75
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep (2017) 0.75
Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet (2000) 8.08
The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem (2001) 4.81
Cranberry juice and urinary tract infection. Clin Infect Dis (2004) 2.68
Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis (2002) 1.59
Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res (1998) 1.57
Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis. Biochemistry (1998) 1.56
Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors. Leuk Res (1997) 1.48
Molecular cloning and characterization of Porphyromonas gingivalis lysine-specific gingipain. A new member of an emerging family of pathogenic bacterial cysteine proteinases. J Biol Chem (1997) 1.43
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol (2001) 1.41
Optic neuritis complicating west nile virus meningitis in a young adult. Infection (2003) 1.39
Successful emergency percutaneous balloon mitral valvotomy in a patient with massive left atrial thrombosis: utility of transesophageal echocardiographic monitoring. Cardiology (1991) 1.39
Accuracy and reliability of dosing equations to individualize theophylline treatment of apnea of prematurity. Pharmacotherapy (1995) 1.39
Sterility of filgrastim (G-CSF) in syringes. Ann Pharmacother (1996) 1.38
Production, purification, and characterization of recombinant maspin proteins. J Biol Chem (1994) 1.38
Squamous cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J Biol Chem (1997) 1.37
maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res (1998) 1.32
Endocarditis caused by Staphylococcus warneri on a normal aortic valve following vasectomy. Can Med Assoc J (1984) 1.31
The serpins: evolution and adaptation in a family of protease inhibitors. Cold Spring Harb Symp Quant Biol (1987) 1.30
The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res (2000) 1.28
Homoharringtonine: history, current research, and future direction. Cancer (2001) 1.25
Septicemia caused by the gram-negative bacterium CDC IV c-2 in an immunocompromised human. J Clin Microbiol (1986) 1.22
Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas (2000) 1.20
Isolation of Mycoplasma hominis from the blood of men with multiple trauma and fever. JAMA (1982) 1.15
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood (1997) 1.13
An increased familial frequency of gallstones. Gastroenterology (1983) 1.13
Genetic variation of Porphyromonas gingivalis genes encoding gingipains, cysteine proteinases with arginine or lysine specificity. Biol Chem (1998) 1.10
Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation. Biochem J (1988) 1.06
Clinical and quality of life outcomes of laparoscopic and open splenectomy for haematological diseases. Eur J Surg (2001) 1.02
Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer (1998) 1.01
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol (1998) 1.00
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene (2010) 1.00
Failure of fluconazole therapy for sternal osteomyelitis due to Candida albicans. Clin Infect Dis (1994) 1.00
Attenuating mutations in coxsackievirus B3 map to a conformational epitope that comprises the puff region of VP2 and the knob of VP3. J Virol (2004) 0.99
Concentration of ciprofloxacin in human prostatic tissue after oral administration. Antimicrob Agents Chemother (1986) 0.97
Interaction between the alpha-T catenin gene (VR22) and APOE in Alzheimer's disease. J Med Genet (2005) 0.97
Pyogenic sacroiliitis in pregnancy. Int J Gynaecol Obstet (1999) 0.96
Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med (1997) 0.95
A case of lymphogranuloma venereum of 20 years' duration. Isolation of Chlamydia trachomatis from perianal lesions. Br J Vener Dis (1980) 0.95
Pericapsular osteotomy of the ilium for the treatment of congenitally dislocated hips. Clin Orthop Relat Res (1974) 0.94
Three-state unfolding and self-association of maspin, a tumor-suppressing serpin. J Biol Chem (1999) 0.94
p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. Int J Mol Med (1998) 0.94
Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence of pharyngeal gonorrhoea. Int J STD AIDS (2008) 0.94
Concentrations of ciprofloxacin in human liver, gallbladder, and bile after oral administration. Eur J Clin Pharmacol (1987) 0.93
Pseudomembranous colitis: report of a severe case with unusual clinical signs in a young nurse. Dis Colon Rectum (2000) 0.93
Comparative periurethral bacteriology of uncircumcised and circumcised males. Genitourin Med (1997) 0.93
Clinical trials referral resource. Clinical trials of MGI-114. Oncology (Williston Park) (1999) 0.93
Left ventricular papillary fibroelastoma with coronary embolization. Eur J Cardiothorac Surg (1989) 0.92
Detection of two types of hemoglobin (HbA and HbF) in single erythrocytes by fluorescent antibody technique. Exp Cell Res (1967) 0.91
Histoplasmosis in the eastern Caribbean: a preliminary survey of the incidence of the infection. J Trop Med Hyg (1981) 0.90
Bacteremic hypocalcemia. A comparison between the calcium levels of bacteremic and nonbacteremic patients with infection. Arch Intern Med (1987) 0.90
Interaction of subtilisins with serpins. Protein Sci (1996) 0.90
Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol (1995) 0.90
Cross resistance to ciprofloxacin and other antimicrobial agents among clinical isolates of Acinetobacter calcoaceticus biovar anitratus. Antimicrob Agents Chemother (1990) 0.89
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother (2011) 0.89
Increasing incidence of gonorrhea in Israel associated with countrywide dissemination of a ciprofloxacin-resistant strain. Eur J Clin Microbiol Infect Dis (2002) 0.88
Modified thioglycolate medium: a simple and reliable means for detection of Trichomonas vaginalis. J Clin Microbiol (1996) 0.88
In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis (2001) 0.88
Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood (1993) 0.88
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol (2000) 0.87
The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs (1995) 0.87
Concentration of norfloxacin in human gallbladder tissue and bile after single-dose oral administration. Antimicrob Agents Chemother (1987) 0.87
Allopurinol-induced toxic epidermal necrolysis. Int J Dermatol (1984) 0.86
Induction of apoptosis in breast cancer cells by TPA. Oncogene (1998) 0.86
Lymphadenopathy in celiac disease: not always a sign of lymphoma. Am J Gastroenterol (1988) 0.86
Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol (1993) 0.85
Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Cancer Res (2000) 0.84
Penetration of third-generation cephalosporins into human peritoneal tissue. Chemotherapy (1989) 0.84
Failure of oral ketoconazole to cure cutaneous ulcers caused by Leishmania braziliensis. Cutis (1986) 0.84
Gastric microbiota in elderly patients fed via nasogastric tubes for prolonged periods. J Hosp Infect (2006) 0.83
Mycoplasma hominis septicemia after heart surgery. Am J Med (1988) 0.83
Use of adsorptive mechanisms in continuous renal replacement therapies in the critically ill. Kidney Int Suppl (1999) 0.83
A retrospective six-year national survey of P. multocida infections in Israel. Scand J Infect Dis (2009) 0.83
A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. Hum Gene Ther (2009) 0.82
Recurrent breast abscesses caused by Corynebacterium minutissimum. J Clin Microbiol (1984) 0.82
Phase II study of bryostatin 1 in patients with relapsed multiple myeloma. Invest New Drugs (2001) 0.82
Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines. Anticancer Drugs (2000) 0.82
Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation (1993) 0.82
Evaluation of prajmalium-induced cholestasis by immunologic tests. Arch Intern Med (1981) 0.82
Mycoplasma hominis septicemia in a burned infant. J Pediatr (1981) 0.82
Corynebacterium group JK septicemia: community-acquired infection in an apparently immunocompetent patient. Isr J Med Sci (1984) 0.82
Penetration of ofloxacin into human lung tissue following a single oral dose of 200 milligrams. Antimicrob Agents Chemother (1991) 0.81
Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection (1987) 0.81
Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol (2000) 0.81
Left atrial myxoma: excision guided by transesophageal cross-sectional echocardiography. Int J Cardiol (1990) 0.81
Penetration of cefetamet pivoxil and cefuroxime axetil into the maxillary sinus mucosa at steady state. Antimicrob Agents Chemother (1996) 0.81
Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis. Hematol Oncol (1990) 0.81
Levels of chemerin and interleukin 8 in the synovial fluid of patients with inflammatory arthritides and osteoarthritis. Clin Exp Rheumatol (2014) 0.81